PerkinElmer, Inc. (PKI)

127.58 +2.48 (+1.98%) At close: 04:03PM EDT

PerkinElmer, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.perkinelmer.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 16,700

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Prahlad R. Singh Ph.D.	CEO, Pres & Director	3.23M	1.3M	1965
Mr. Maxwell Krakowiak	Sr. VP & CFO	814.58k	N/A	1990
Mr. Tajinder Vohra	Sr. VP of Global Operations	927.24k	605.26k	1966
Mr. Joel S. Goldberg	Sr. VP of Admin., Gen. Counsel & Sec.	1.29M	3.49M	1969
Mr. Daniel R. Tereau	Sr. VP of Strategy & Bus. Devel.	967.97k	1.36M	1968
Mr. Andrew Okun	VP, Chief Accounting Officer & Treasurer	N/A	N/A	1970
Mr. Stephen Barr Willoughby	Sr. VP of Investor Relations & Head of ESG	N/A	N/A	N/A
Mr. Robert Francis Friel	Advisor	N/A	N/A	1956
Ms. Miriame Victor	Sr. VP & Chief Commercial Officer	N/A	N/A	1981
Dr. Masoud Toloue Ph.D.	Sr. VP of Diagnostics	N/A	N/A	1980

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Corporate governance

PerkinElmer, Inc.’s ISS governance QualityScore as of 1 March 2023 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.